JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1993; 22:1897-1901
© 1993 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiedermann, C.
Right arrow Articles by Braunsteiner, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiedermann, C.
Right arrow Articles by Braunsteiner, H

Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha

CJ Wiedermann, H Beimpold, M Herold, E Knapp, and H Braunsteiner

Department of Internal Medicine, University of Innsbruck, Austria.

OBJECTIVES. The purpose of this study was to examine the role of tumor necrosis factor-alpha and tetrahydrobiopterin and superoxide anion release from neutrophils in severe chronic heart failure. BACKGROUND. Previous studies have demonstrated elevated production of tumor necrosis factor-alpha and free radical-induced endothelial cell damage in severe heart failure. METHODS. Plasma and serum levels of immunoreactive interleukin-1, interleukin-6, interferon-gamma, neopterin and tumor necrosis factor-alpha and the release of superoxide anions from circulating neutrophils both at basal conditions and after triggering with f-Met-Leu-Phe or phorbol 12-myristate 13-acetate were measured in 16 patients with severe heart failure and in 11 healthy control subjects. RESULTS. Circulating levels of tumor necrosis factor-alpha and neopterin were elevated in patients with heart failure compared with values in control subjects. A significant correlation between the two was found. Basal and phorbolester-triggered release of oxygen radicals from neutrophils was not affected in patients with heart failure. However, formylpeptide-stimulated release of oxygen radicals by neutrophils was significantly reduced. CONCLUSIONS. Suppressed neutrophil function in patients with heart failure exhibiting elevated levels of tumor necrosis-alpha factor may indicate self-protection against the deleterious effects of neutrophil-derived oxygen radicals. Through induction of tetrahydrobiopterin synthesis (as reflected by increased neopterin), tumor necrosis factor-alpha may affect nitric oxide synthesis.


This article has been cited by other articles:


Home page
ANGIOLOGYHome page
J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater
Cardiac Function, Inflammatory Mediators and Mortality in Critical Limb Ischemia
Angiology, August 1, 2006; 57(4): 437 - 444.
[Abstract] [PDF]


Home page
Circ. Res.Home page
R. A. Ahokas, K. J. Warrington, I. C. Gerling, Y. Sun, L. A. Wodi, P. A. Herring, L. Lu, S. K. Bhattacharya, A. E. Postlethwaite, and K. T. Weber
Aldosteronism and Peripheral Blood Mononuclear Cell Activation: A Neuroendocrine-Immune Interface
Circ. Res., November 14, 2003; 93 (10): e124 - e135.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. S. Bradham, B. Bozkurt, H. Gunasinghe, D. Mann, and F. G. Spinale
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective
Cardiovasc Res, March 1, 2002; 53(4): 822 - 830.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. Kell, A. Haunstetter, T.J. Dengler, C. Zugck, W. Kubler, and M. Haass
Do cytokines enable risk stratification to be improved in NYHA functional class III patients?. Comparison with other potential predictors of prognosis
Eur. Heart J., January 1, 2002; 23(1): 70 - 78.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A.L. Clark, M. Loebe, E.V. Potapov, K. Egerer, C. Knosalla, R. Hetzer, and S.D. Anker
Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight
Eur. Heart J., December 2, 2001; 22(24): 2275 - 2283.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
C.-W. Kong, T.-G. Hsu, F.-J. Lu, W.-L. Chan, and K. Tsai
Leukocyte mitochondria depolarization and apoptosis in advanced heart failure: clinical correlations and effect of therapy
J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1693 - 1700.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al.
High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure
J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1587 - 1593.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
B. Bozkurt
Activation of cytokines as a mechanism of disease progression in heart failure
Ann Rheum Dis, November 1, 2000; 59(90001): i90 - 93.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
A. Gottsater, I. Anwaar, K.-F. Eriksson, I. Mattiasson, F. Lindgarde, and A. Gottsater
Homocysteine Is Related to Neopterin and Endothelin-1 in Plasma of Subjects with Disturbed Glucose Metabolism and Reference Subjects
Angiology, June 1, 2000; 51(6): 489 - 497.
[Abstract] [PDF]


Home page
Eur Heart JHome page
C Berry and A.L Clark
Catabolism in chronic heart failure
Eur. Heart J., April 1, 2000; 21(7): 521 - 532.
[PDF]


Home page
Eur Heart JHome page
M Tendera and H Wysocki
TNF-{alpha} in patients with chronic failure is not only a proinflammatory cytokine
Eur. Heart J., October 2, 1999; 20(20): 1445 - 1446.
[PDF]


Home page
J Am Coll CardiolHome page
Z. Dibbs, J. Thornby, B. G. White, and D. L. Mann
Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials
J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1935 - 1942.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
E. H. Herrera-Garza, S. J. Stetson, A. Cubillos-Garzon, M. T. Vooletich, J. A. Farmer, and G. Torre-Amione
Tumor Necrosis Factor-{alpha}: A Mediator of Disease Progression in the Failing Human Heart
Chest, April 1, 1999; 115(4): 1170 - 1174.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Bozkurt, S. B. Kribbs, F. J. Clubb Jr, L. H. Michael, V. V. Didenko, P. J. Hornsby, Y. Seta, H. Oral, F. G. Spinale, and D. L. Mann
Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor-{alpha} Promote Progressive Left Ventricular Dysfunction and Remodeling in Rats
Circulation, April 14, 1998; 97(14): 1382 - 1391.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Ferrari
Tumor necrosis factor in CHF: a double facet cytokine
Cardiovasc Res, March 1, 1998; 37(3): 554 - 559.
[Full Text] [PDF]


Home page
CirculationHome page
G. Torre-Amione, S. Kapadia, J. Lee, J.-B. Durand, R. D. Bies, J. B. Young, and D. L. Mann
Tumor Necrosis Factor-{alpha} and Tumor Necrosis Factor Receptors in the Failing Human Heart
Circulation, February 15, 1996; 93(4): 704 - 711.
[Abstract] [Full Text]


Home page
CirculationHome page
M. Packer
Is Tumor Necrosis Factor an Important Neurohormonal Mechanism in Chronic Heart Failure?
Circulation, September 15, 1995; 92(6): 1379 - 1382.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1993 by the American College of Cardiology Foundation.